CEO of Utd Therapeutic (
) Martine A. Rothblatt bought 13,649 shares on June 13, 2012, at
an average price of $43.6. The total transaction amount is
$595,096. Utd Therapeutic is a biotechnology company focused on
combating cardiovascular, inflammatory and infectious diseases
with unique therapeutic products. Utd Therapeutic has a market
cap of $2.32 billion; its shares were traded at around $45.42
with a P/E ratio of 9.8 and P/S ratio of 3.1.
CEO Martine Rothblatt recently traded two times in UTHR, both
times increasing her position in the company. On 12/30/2011, she
bought 11,823 shares of the company at an average price of
$43.92. The price of the stock has since increased by 3.42%.
However, other insiders are decreasing their shares in the
company. President and COO Roger Jeffs sold 5,000 shares of the
company on 2/3/2012, while Executive Vice President and General
Counsel Paul Mahon sold 72,000 shares at an average price of $50.
Director Christopher Patusky sold off 7,500 shares over the
course of two months in early 2012.
CEO Martine Rothblatt works in the field of communication
satellite law and is also engaged in various life science
projects such as the Human Genome Project. She was the second
highest-compensated executive in the District of Columbia in
2007. She graduated from UCLA and previously worked as an
bought 15,300 shares of UTHR in the quarter that ended on
03/31/2012, which is 0.035% of the $2.08 billion portfolio of
owns 165,063 shares as of 03/31/2012, an increase of 82.68% from
the previous quarter. This position accounts for 0.68% of the
$1.15 billion portfolio of Gotham Capital.
owns 1,787,000 shares as of 03/31/2012, which accounts for 0.4%
of the $20.91 billion portfolio of Vanguard Health Care Fund.
Revenue per share for UTHR increased at an average of 46.1% per
year over the past 10 years, 29.2% over the past five years, and
29.9% over the past 12 months. Earnings per share were
historically mostly positive, with three out of the last ten
years reporting negative profits. UTHR holds about $400 million
in cash, but has $71.45 million in long-term debt. About 80% of
the company's total current assets are in cash. UTHR has a
predictability rating of 1 star.
About GuruFocus: GuruFocus.com tracks the stocks picks and
portfolio holdings of the world's best investors. This value
investing site offers stock screeners and valuation tools. And
publishes daily articles tracking the latest moves of the world's
best investors. GuruFocus also provides promising stock ideas in
3 monthly newsletters sent to